153 related articles for article (PubMed ID: 31695025)
1. A functional genetic screen identifies the Mediator complex as essential for SSX2-induced senescence.
Brückmann NH; Bennedsen SN; Duijf PHG; Terp MG; Thomassen M; Larsen M; Pedersen CB; Kruse T; Alcaraz N; Ditzel HJ; Gjerstorff MF
Cell Death Dis; 2019 Nov; 10(11):841. PubMed ID: 31695025
[TBL] [Abstract][Full Text] [Related]
2. Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instability.
Greve KB; Lindgreen JN; Terp MG; Pedersen CB; Schmidt S; Mollenhauer J; Kristensen SB; Andersen RS; Relster MM; Ditzel HJ; Gjerstorff MF
Mol Oncol; 2015 Feb; 9(2):437-49. PubMed ID: 25363656
[TBL] [Abstract][Full Text] [Related]
3. The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation.
de Bruijn DR; Allander SV; van Dijk AH; Willemse MP; Thijssen J; van Groningen JJ; Meltzer PS; van Kessel AG
Cancer Res; 2006 Oct; 66(19):9474-82. PubMed ID: 17018603
[TBL] [Abstract][Full Text] [Related]
4. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma.
Kawai A; Woodruff J; Healey JH; Brennan MF; Antonescu CR; Ladanyi M
N Engl J Med; 1998 Jan; 338(3):153-60. PubMed ID: 9428816
[TBL] [Abstract][Full Text] [Related]
5. The impact of chromosomal translocation locus and fusion oncogene coding sequence in synovial sarcomagenesis.
Jones KB; Barrott JJ; Xie M; Haldar M; Jin H; Zhu JF; Monument MJ; Mosbruger TL; Langer EM; Randall RL; Wilson RK; Cairns BR; Ding L; Capecchi MR
Oncogene; 2016 Sep; 35(38):5021-32. PubMed ID: 26947017
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines.
dos Santos NR; Torensma R; de Vries TJ; Schreurs MW; de Bruijn DR; Kater-Baats E; Ruiter DJ; Adema GJ; van Muijen GN; van Kessel AG
Cancer Res; 2000 Mar; 60(6):1654-62. PubMed ID: 10749136
[TBL] [Abstract][Full Text] [Related]
7. SYT-SSX fusion genes in synovial sarcoma of the thorax.
Yano M; Toyooka S; Tsukuda K; Dote H; Morimoto Y; Ohata N; Ichimura K; Aoe M; Date H; Shimizu N
Lung Cancer; 2004 Jun; 44(3):391-7. PubMed ID: 15140553
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of molecular and cytogenetic findings in synovial sarcoma.
Panagopoulos I; Mertens F; Isaksson M; Limon J; Gustafson P; Skytting B; Akerman M; Sciot R; Dal Cin P; Samson I; Iliszko M; Ryoe J; Dêbiec-Rychter M; Szadowska A; Brosjö O; Larsson O; Rydholm A; Mandahl N
Genes Chromosomes Cancer; 2001 Aug; 31(4):362-72. PubMed ID: 11433527
[TBL] [Abstract][Full Text] [Related]
9. Co-existence of SYT-SSX1 and SYT-SSX2 fusions in synovial sarcomas.
Yang K; Lui WO; Xie Y; Zhang A; Skytting B; Mandahl N; Larsson C; Larsson O
Oncogene; 2002 Jun; 21(26):4181-90. PubMed ID: 12037676
[TBL] [Abstract][Full Text] [Related]
10. MED14 and MED1 differentially regulate target-specific gene activation by the glucocorticoid receptor.
Chen W; Rogatsky I; Garabedian MJ
Mol Endocrinol; 2006 Mar; 20(3):560-72. PubMed ID: 16239257
[TBL] [Abstract][Full Text] [Related]
11. Nuclear localization of SYT, SSX and the synovial sarcoma-associated SYT-SSX fusion proteins.
dos Santos NR; de Bruijn DR; Balemans M; Janssen B; Gärtner F; Lopes JM; de Leeuw B; Geurts van Kessel A
Hum Mol Genet; 1997 Sep; 6(9):1549-58. PubMed ID: 9285793
[TBL] [Abstract][Full Text] [Related]
12. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients.
Ladanyi M; Antonescu CR; Leung DH; Woodruff JM; Kawai A; Healey JH; Brennan MF; Bridge JA; Neff JR; Barr FG; Goldsmith JD; Brooks JS; Goldblum JR; Ali SZ; Shipley J; Cooper CS; Fisher C; Skytting B; Larsson O
Cancer Res; 2002 Jan; 62(1):135-40. PubMed ID: 11782370
[TBL] [Abstract][Full Text] [Related]
13. The synovial sarcoma translocation protein SYT-SSX2 recruits beta-catenin to the nucleus and associates with it in an active complex.
Pretto D; Barco R; Rivera J; Neel N; Gustavson MD; Eid JE
Oncogene; 2006 Jun; 25(26):3661-9. PubMed ID: 16462762
[TBL] [Abstract][Full Text] [Related]
14. SYT-SSX1 and SYT-SSX2 interfere with repression of E-cadherin by snail and slug: a potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma.
Saito T; Nagai M; Ladanyi M
Cancer Res; 2006 Jul; 66(14):6919-27. PubMed ID: 16849535
[TBL] [Abstract][Full Text] [Related]
15. The cancer-related protein SSX2 interacts with the human homologue of a Ras-like GTPase interactor, RAB3IP, and a novel nuclear protein, SSX2IP.
de Bruijn DR; dos Santos NR; Kater-Baats E; Thijssen J; van den Berk L; Stap J; Balemans M; Schepens M; Merkx G; van Kessel AG
Genes Chromosomes Cancer; 2002 Jul; 34(3):285-98. PubMed ID: 12007189
[TBL] [Abstract][Full Text] [Related]
16. Molecular diagnosis of synovial sarcoma and characterization of a variant SYT-SSX2 fusion transcript.
Fligman I; Lonardo F; Jhanwar SC; Gerald WL; Woodruff J; Ladanyi M
Am J Pathol; 1995 Dec; 147(6):1592-9. PubMed ID: 7495284
[TBL] [Abstract][Full Text] [Related]
17. Molecular detection of SS18-SSX fusion gene transcripts by cRNA in situ hybridization in synovial sarcoma using formalin-fixed, paraffin-embedded tumor tissue specimens.
Kanemitsu S; Hisaoka M; Shimajiri S; Matsuyama A; Hashimoto H
Diagn Mol Pathol; 2007 Mar; 16(1):9-17. PubMed ID: 17471153
[TBL] [Abstract][Full Text] [Related]
18. Detection of the SYT-SSX fusion transcripts in formaldehyde-fixed, paraffin-embedded tissue: a reverse transcription polymerase chain reaction amplification assay useful in the diagnosis of synovial sarcoma.
Lasota J; Jasinski M; Debiec-Rychter M; Szadowska A; Limon J; Miettinen M
Mod Pathol; 1998 Jul; 11(7):626-33. PubMed ID: 9688183
[TBL] [Abstract][Full Text] [Related]
19. Arginine and glutamate-rich 1 (ARGLU1) interacts with mediator subunit 1 (MED1) and is required for estrogen receptor-mediated gene transcription and breast cancer cell growth.
Zhang D; Jiang P; Xu Q; Zhang X
J Biol Chem; 2011 May; 286(20):17746-54. PubMed ID: 21454576
[TBL] [Abstract][Full Text] [Related]
20. The SYT protein involved in the t(X;18) synovial sarcoma translocation is a transcriptional activator localised in nuclear bodies.
Brett D; Whitehouse S; Antonson P; Shipley J; Cooper C; Goodwin G
Hum Mol Genet; 1997 Sep; 6(9):1559-64. PubMed ID: 9285794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
